A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.

Research exploring novel therapies to fight against bladder cancer and a world-first asthma study are among 18 Western projects drawing more than $15 ...

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

According to a real-world study, tezepelumab is an effective add-on biologic with a rapid onset of action for patients with both T2-high and T2-low severe asthma. The study was published ...

The National Medical Products Administration (NMPA) approved an investigational new drug (IND) application for WIN378 to ...

A digital asthma self-management program enhanced symptom control; however, it revealed racial disparities in engagement, highlighting the need for culturally tailored interventions.

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", HKEX: 6990) today announced that its partner, Windward Bio AG ("Windward Bio") has launched its Phase 2 POLARIS ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

The latest UK asthma guidelines1 clearly define the role of Fractional exhaled Nitric Oxide (FeNO) testing in both diagnosing ...

With 118 more biologic drugs set to lose patent protection by 2035, the market for their cheaper mimics could be about to boom.

Patients with moderate to severe atopic dermatitis experienced a 71% decrease in Eczema Area and Severity Index scores from baseline through 16 weeks with APG777, an anti-IL-13 antibody from Apogee ...